By Sven Stegemann, PhD, Capsugel
After a decade of cost cutting in product development and manufacturing, many pharmaceutical companies have struggled to meet basic quality standards. In recent years, the U.S. Food and Drug Administration (FDA) has shuttered numerous manufacturing sites and banned a variety of products because of Good Manufacturing Practices (GMP) violations. As a result, many companies have experienced substantial hits to both their corporate reputation and profitability.
What can be done to turn the tide? In many ways, it comes down to a simple shift in mindset: viewing quality in terms of the value it creates, rather than its cost.